About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with ...

Clonal hematopoiesis in chronic lymphocytic leukemia is widespread, shaping cytopenias, cardiovascular risk, and chemotoxicity. As patients age on therapy for their chronic lymphocytic leukemia (CLL), ...

Identification of recurrent genetic abnormalities is important for disease evaluation, optimal risk stratification and treatment planning. Testing for recurrent genetic abnormalities should be ...

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Key Takeaways A highly sensitive DNA test can detect hidden leukemia cells that predict if a patient’s cancer is likely to ...

The Test Before Treat campaign highlights how a patient’s genetic profile can change over time and encourages the use of a blood test to identify mutations to provide important insights into disease ...